About The Study: The results of this study suggest that young breast cancer survivors without a germline pathogenic variant have a low risk of developing a second primary breast cancer in the first 10 years after diagnosis. Findings from germline genetic testing may inform treatment decision-making and follow-up care considerations in this population.
Authors: Kristen D. Brantley, Ph.D., M.P.H., of the Harvard T. H. Chan School of Public Health in Boston, is the corresponding author.
To access the embargoed study: Visit our For The Media website at this link https://media.jamanetwork.com/
(doi:10.1001/jamaoncol.2024.0286)
Editor’s Note: Please see the article for additional information, including other authors, author contributions and affiliations, conflict of interest and financial disclosures, and funding and support.
# # #
Embed this link to provide your readers free access to the full-text article This link will be live at the embargo time https://jamanetwork.com/journals/jamaoncology/fullarticle/10.1001/jamaoncol.2024.0286?guestAccessKey=69248d69-50fe-42e8-9b30-327dba0a1eb6&utm_source=For_The_Media&utm_medium=referral&utm_campaign=ftm_links&utm_content=tfl&utm_term=041124
JAMA Oncology